The service will support Malaria vaccine development and functions of multiple Lab sections for NIH, NIAID, Laboratory of Malaria Immunology and Vaccinology Research (LMIV). The Novel Wheat germ cell-free protein production is performed using plant cells and not animals will be used. Place of service is Matsuyama, Japan.
The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one source available, to maintain continuity of established FDA approvals for the current Malaria vaccine development. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-RML-D-1831022) to Laura Grey at [email protected], by 5:00 pm eastern standard time, Friday January 27th, 2017. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.